SPOTLIGHT: Synthetic Blood touts Phase IIa data


Synthetic Blood International says that a Phase IIa trial of OxyCyte hit its primary endpoint in traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.